Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients

[1]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[2]  A. Santoro,et al.  Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study , 2017, Journal of Nephrology.

[3]  E. Manzato,et al.  Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non‐valvular atrial fibrillation , 2016, Journal of thrombosis and haemostasis : JTH.

[4]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  D. Brancaccio,et al.  Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study , 2016, American Journal of Nephrology.

[6]  A. Tripodi,et al.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  P. Verhamme,et al.  Reversal of dabigatran by idarucizumab: when and how? , 2016, Expert review of hematology.

[8]  G. Lip,et al.  Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. , 2016, JAMA cardiology.

[9]  T. Steiner,et al.  Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation , 2016, Critical Care.

[10]  P. Schulman,et al.  Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.

[11]  M. Tinetti,et al.  Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. , 2016, JAMA cardiology.

[12]  F. Gaita,et al.  Effects of Oral Anticoagulant Therapy in Medical Inpatients ≥65 Years With Atrial Fibrillation. , 2016, The American journal of cardiology.

[13]  G. Caleb Alexander,et al.  Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.

[14]  R. Rossaint,et al.  Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model , 2015, Thrombosis and Haemostasis.

[15]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  A. Själander,et al.  Warfarin persistence among stroke patients with atrial fibrillation. , 2015, Thrombosis research.

[17]  C. Spivey,et al.  Stroke associated with discontinuation of warfarin therapy for atrial fibrillation , 2015, Current medical research and opinion.

[18]  A. Di Minno,et al.  Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. , 2015, Blood reviews.

[19]  T. Steiner,et al.  Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.

[20]  Bcps,et al.  Idarucizumab for dabigatran reversal , 2015 .

[21]  S. Yusuf,et al.  Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. , 2015, Journal of the American College of Cardiology.

[22]  F. Gaita,et al.  Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study. , 2015, International journal of cardiology.

[23]  S. Corrao,et al.  Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. , 2015, European journal of internal medicine.

[24]  M. Turakhia,et al.  Site-level variation in and practices associated with dabigatran adherence. , 2015, JAMA.

[25]  H. Heidbuchel,et al.  Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  A. Santoro,et al.  Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  E. Edelman,et al.  Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.

[28]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[29]  M. Lamberts,et al.  Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.

[30]  J. Halperin,et al.  Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. , 2014, The Canadian journal of cardiology.

[31]  G. Lip,et al.  Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. , 2014, The American journal of medicine.

[32]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[33]  R. Rossaint,et al.  Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model , 2014, Critical Care.

[34]  A. Abdul-Rahim,et al.  Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation , 2014, Heart.

[35]  A. Santoro,et al.  The nephrologist’s anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation , 2014, Journal of Nephrology.

[36]  G. Lip,et al.  Patient outcomes using the European label for dabigatran , 2013, Thrombosis and Haemostasis.

[37]  S. Yusuf,et al.  Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.

[38]  Emily C. O'Brien,et al.  Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). , 2014, American heart journal.

[39]  A. Maggioni,et al.  Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. , 2013, International journal of cardiology.

[40]  J. Eikelboom,et al.  Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. , 2013, Circulation.

[41]  L. Ferrucci,et al.  Glomerular Filtration Rate Equations Overestimate Creatinine Clearance in Older Individuals Enrolled in the Baltimore Longitudinal Study on Aging: Impact on Renal Drug Dosing , 2013, Pharmacotherapy.

[42]  R. Mathur,et al.  Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study , 2013, BMJ Open.

[43]  S. Shafi,et al.  A case of dabigatran-associated acute renal failure. , 2013, WMJ : official publication of the State Medical Society of Wisconsin.

[44]  J. Eikelboom,et al.  New oral anticoagulants in elderly patients. , 2013, Best practice & research. Clinical haematology.

[45]  D. Chae,et al.  The Occurrence of Warfarin-Related Nephropathy and Effects on Renal and Patient Outcomes in Korean Patients , 2013, PloS one.

[46]  T. Gomes,et al.  Rates of hemorrhage during warfarin therapy for atrial fibrillation , 2013, Canadian Medical Association Journal.

[47]  E. Schaeffner,et al.  Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older , 2012, Annals of Internal Medicine.

[48]  E. Teal,et al.  Perceived or Actual Barriers to Warfarin Use in Atrial Fibrillation Based on Electronic Medical Records , 2012, American journal of therapeutics.

[49]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[50]  J. Cracowski,et al.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.

[51]  Mark Crowther,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[52]  W. Ageno,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis , 2012 .

[53]  W. Ageno,et al.  Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Oral Anticoagulant Therapy : Antithrombotic , 2012 .

[54]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[55]  G. Mead,et al.  Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. , 2011, Age and ageing.

[56]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[57]  B. Rovin,et al.  Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. , 2011, Journal of the American Society of Nephrology : JASN.

[58]  W. Ageno,et al.  Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation , 2011, Circulation.

[59]  B. Rovin,et al.  Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. , 2011, Kidney international.

[60]  Bertram L Kasiske,et al.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.

[61]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[62]  G. Lip,et al.  Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. , 2011, Journal of the American College of Cardiology.

[63]  Elsayed Z Soliman,et al.  Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2011, Circulation. Arrhythmia and electrophysiology.

[64]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[65]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[66]  L. Hebert,et al.  Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[67]  D. Singer,et al.  The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation , 2009, Annals of Internal Medicine.

[68]  M. Crowther,et al.  Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose , 2009, Transfusion.

[69]  W. Baker,et al.  Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.

[70]  D. Singer,et al.  Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.

[71]  D. Singer,et al.  Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.

[72]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[73]  S. Frostick,et al.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.

[74]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[75]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[76]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[77]  E. Hylek,et al.  Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation , 2006, Stroke.

[78]  M. Rich,et al.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. , 2005, The American journal of medicine.

[79]  F. Molnar,et al.  The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy , 2005, Thrombosis journal.

[80]  A. Garg,et al.  Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). , 2002, Journal of the American Society of Nephrology : JASN.

[81]  D. Singer,et al.  Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.

[82]  A. Laupacis,et al.  Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. , 1999, Archives of internal medicine.

[83]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.